IMPLICATIONS FOR PATIENT CARE: Combining PSMA PET with HOXB13 RNA or protein expression profiling of biopsy specimens or resected tumors may enable early improved profiling of high-risk PC in the clinical setting. The gene discussed is HOXB13; the disease is pachyonychia congenita.